PATENT CLAIM ANALYSIS

Application Number: 15941644
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["424", "408000"]

Abstract:
Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.

Claim (Index 11):
The capsule formulation of  claim 1 , wherein the capsule formulation exhibits an in vitro dissolution profile when tested using a USP paddle (Type II) apparatus at a temperature of 37\u00b0 C.\u00b10.2\u00b0 C. and RPM of 50\u00b10.1 per minute using 1000 mL phosphate buffered saline (pH=7.3\u00b10.1) as the dissolution medium of\n about 20 to about 30% release at 1 hour, \n about 50 to about 60% release at 6 hours, and \n about 90 to about 100% release at 12 hours; and \n optionally further wherein the capsule formulation exhibits an in vitro dissolution profile of \n about 25 to about 35% release at 2 hours, \n about 40 to about 50% release at 4 hours, \n about 75 to about 85% release at 8 hours, \n about 80 to about 95% release at 10 hours, and \n about 95 to about 100% release at 20 hours.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.14815
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15912438', '13498751', '12097163', '14776386', '14062759']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7403076992288884
- 35 USC 102 Novelty (BERT): 0.5050628569865443
- Combined Prediction Score: 0.716783215004654
- Mean Citation Score: 224.737068
- Max Citation Score: 237.49814
- Similarity Product: 155.24460535805466

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test